



July 5, 2012

The National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sirs,

Sub: Disclosure pursuant to Clause 36 of the Listing Agreement.

Enclosed is a press release as regards receipt of USFDA approval for the Company's Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg which are the AB-rated generic equivalent of LYRICA® (Pregabalin) capsules for neuropathic pain associated with diabetic peripheral neuropathy, post herpetic neuralgia, adjunctive therapy for adult patients with partial onset seizures and fibromyalgia.

The above may be considered as a disclosure pursuant to Clause 36 of the Listing Agreement.

Thanking you,

Yours faithfully,
For **LUPIN LIMITED**



R. V. SATAM

COMPANY SECRETARY & COMPLIANCE OFFICER

Encl.: a/a.

Lupin Limited

Registered Office : 159, C.S.T. Road, Kalina, Santacruz (East), Mumbai - 400 098, India. Tel.: (91-22) 6640 2323. Fax: (91-22) 6640 2445. Website: www.lupinworld.com



BSE : 500257

NSE: Lupin

REUTERS: LUPN.BO

BLOOMBERG: LPC IN

Lupin receives FDA approval for Generic LYRICA®

Mumbai / Baltimore, July 05, 2012: Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has received final approval for its Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg from the United States Food and Drugs Administration (FDA) to market a generic version of C.P. Pharmaceuticals C.V., LYRICA® (Pregabalin) capsules.

Lupin's Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg are the AB-rated generic equivalent of LYRICA® capsules, which is indicated for neuropathic pain associated with diabetic peripheral neuropathy, post herpetic neuralgia, adjunctive therapy for adult patients with partial onset seizures and fibromyalgia.

LYRICA® Capsules had annual U.S sales of approximately \$1.8 billion for the twelve months ending March 2012 (IMS Health Sales Data).

About Lupin Limited

Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing a wide range of generic and branded formulations and APIs. The Company today has significant presence in the Cardiovascular, Diabetology, Asthma, Paediatrics, CNS, GI, Anti-Infective and NSAID space in addition to holding global leadership positions in the Anti-TB and Cephalosporin segments.

Lupin is the 5th largest and fastest growing generics player in the US (5.3% market share by prescriptions, IMS Health), the only Asian company to achieve that distinction. The company is also the fastest growing top 10 pharmaceutical player in India, Japan and South Africa (IMS).

For the financial year ended March 2012, Lupin's Consolidated Revenues and Profit after Tax were Rs.70,829 Million (USD 1.42 Billion) and Rs. 8,676 Million (USD 190 million) respectively. Please visit <http://www.lupinworld.com> for more information.

Lupin Pharmaceuticals, Inc. is the wholly owned U.S. subsidiary of Lupin Limited. Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit <http://www.lupinpharmaceuticals.com>.

For further information or queries, please contact -

Shamsher Gorawara

Head - Corporate Communications

Lupin Limited:

Ph: +91 98 20 338 555

Email: shamshergorawara@lupinpharma.com

or

Rajiv Pillai

Head - Investor Relations

Lupin Limited:

Ph: +91 98 20 552 083

Email: rajivpillai@lupinpharma.com

Safe Harbor Statement

*LYRICA® is a registered trademark of C.P. Pharmaceuticals, C.V. a wholly owned subsidiary of Pfizer, Inc.